指南与共识特殊人群用药治疗药物监测与药物基因组学

儿科药物开发与应用如何从组学技术中获益:c4c专家工作组白皮书

How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper.
指南 / 共识 · Br J Clin Pharmacol · 2022-02-09

该白皮书由c4c专家工作组撰写,探讨组学技术在儿科药物治疗中的应用前景与挑战。文章指出儿科用药安全性和有效性受限于前瞻性临床试验高质量数据缺乏,组学技术可通过靶向和非靶向分子的系统表征与定量提供补充信息,但在常规应用前需应对发育过程分群、患者数量与生物材料有限等挑战,最终目标是将组学技术与人工智能等创新分析工具早期结合。

要点

  • 组学技术可为儿科药物治疗提供靶向与非靶向分子的补充信息,助力生物标志物建立。
  • 儿科应用组学需考虑发育过程并按特定年龄组细分,因发育变化明显影响组学数据。
  • 新生儿和早产儿患者数量及生物材料有限,需先进试验设计、非侵入性标志物和创新生物样本库概念。

核心结论

  • 组学技术有潜力通过补充信息支持儿科药物治疗生物标志物的建立,但常规应用前需克服发育分群、样本有限等多重挑战。
  • 最终目标是将组学技术与人工智能等创新分析工具在早期阶段结合,以识别复杂表型和患者亚群,改善儿科药物开发。

研究设计与样本

  • 本文为c4c专家工作组白皮书,基于专家意见阐述组学技术在儿科药物开发与应用中的前景与挑战。

主要发现

  • 儿科药物治疗的安全性和有效性受限于前瞻性临床试验高质量数据缺乏,尤其是早产儿、新生儿和婴儿。
  • 组学技术包括基因组学、表观基因组学、转录组学、蛋白质组学、代谢组学和微生物组学,以及患者表型。
  • 组学技术部分具有假设生成作用,有助于深入理解疾病病理生理学和药理学机制。

临床怎么用

  • 在儿科药物开发中可考虑整合组学技术以补充生物标志物信息,但需按特定年龄组细分并考虑发育变化对组学数据的影响。
  • 针对新生儿和早产儿生物材料有限的问题,可探索非侵入性生物标志物、创新生物样本库概念和先进试验设计。

局限性

  • 组学技术在儿科常规应用前面临发育过程需分年龄组考虑、患者数量有限、生物材料类型和数量受限等挑战。
  • 需要先进试验设计和生物统计方法、非侵入性生物标志物、创新生物样本库概念以及液体活检等分析方法来克服障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The safety and efficacy of pharmacotherapy in children, particularly preterms, neonates and infants, is limited by a paucity of good-quality data from prospective clinical drug trials. A specific challenge is the establishment of valid biomarkers. OMICs technologies may support these efforts by complementary information about targeted and nontargeted molecules through systematic characterization and quantitation of biological samples. OMICs technologies comprise at least genomics, epigenomics, transcriptomics, proteomics, metabolomics and microbiomics in addition to the patient's phenotype. OMICs technologies are in part hypothesis-generating, allowing an in depth understanding of disease pathophysiology and pharmacological mechanisms. Application of OMICs technologies in paediatrics faces major challenges before routine adoption. First, developmental processes need to be considered, including a subdivision into specific age groups as developmental changes clearly impact OMICs data. Second, compared to the adult population, the number of patients is limited as are the type and amount of necessary biomaterial, especially in neonates and preterms. Thus, advanced trial designs and biostatistical methods, noninvasive biomarkers, innovative biobanking concepts including data and samples from healthy children, as well as analytical approaches (eg liquid biopsies) should be addressed to overcome these obstacles. The ultimate goal is to link OMICs technologies with innovative analysis tools, such as artificial intelligence at an early stage. The use of OMICs data based on a feasible approach will contribute to the identification complex phenotypes and subpopulations of patients to improve the development of medicines for children with potential economic advantages.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Neumann E, Schreeck F, Herberg J, et al. How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. Br J Clin Pharmacol. 2022. PMID: 34997627. doi:10.1111/bcp.15216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。